Merit Medical Systems (NASDAQ:MMSI) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Merit Medical Systems (NASDAQ:MMSI) in a report released on Friday,Benzinga reports. The brokerage currently has a $108.00 price objective on the medical instruments supplier’s stock.

Several other research firms have also recently weighed in on MMSI. Robert W. Baird set a $108.00 price objective on shares of Merit Medical Systems in a report on Tuesday, December 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a report on Monday, December 29th. Zacks Research downgraded Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Canaccord Genuity Group upped their price objective on Merit Medical Systems from $93.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Piper Sandler reissued an “overweight” rating and issued a $109.00 target price (up from $105.00) on shares of Merit Medical Systems in a research report on Friday, October 31st. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $105.88.

Merit Medical Systems Stock Down 7.3%

MMSI stock opened at $86.38 on Friday. The stock has a market capitalization of $5.12 billion, a P/E ratio of 44.30, a P/E/G ratio of 2.71 and a beta of 0.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.28 and a quick ratio of 2.86. Merit Medical Systems has a 1-year low of $78.12 and a 1-year high of $111.45. The business has a fifty day moving average price of $87.03 and a 200-day moving average price of $86.62.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.92 EPS for the quarter, topping the consensus estimate of $0.82 by $0.10. Merit Medical Systems had a return on equity of 14.27% and a net margin of 8.02%.The company had revenue of $384.16 million during the quarter, compared to the consensus estimate of $371.69 million. During the same period last year, the company earned $0.86 EPS. Merit Medical Systems’s revenue for the quarter was up 13.0% on a year-over-year basis. Merit Medical Systems has set its FY 2025 guidance at 3.660-3.790 EPS. Equities analysts forecast that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Insider Activity

In other news, Chairman Fred P. Lampropoulos sold 10,000 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $88.04, for a total transaction of $880,400.00. Following the sale, the chairman directly owned 1,019,955 shares in the company, valued at $89,796,838.20. This trade represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 60,000 shares of company stock valued at $5,189,900 over the last three months. Corporate insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Maseco LLP bought a new position in shares of Merit Medical Systems in the second quarter worth about $28,000. MassMutual Private Wealth & Trust FSB raised its stake in Merit Medical Systems by 55.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 134 shares during the period. Salomon & Ludwin LLC purchased a new position in Merit Medical Systems in the 3rd quarter worth approximately $37,000. Bayforest Capital Ltd purchased a new position in shares of Merit Medical Systems in the first quarter worth $41,000. Finally, Danske Bank A S bought a new position in shares of Merit Medical Systems during the 3rd quarter valued at about $42,000. 99.66% of the stock is owned by institutional investors.

Trending Headlines about Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Analysts reaffirmed Buy ratings and maintain upside — Needham reiterated a Buy with a $108 price target and Canaccord kept its Buy stance, signaling continued analyst confidence in MMSI’s growth prospects. Analyst Notes
• Positive Sentiment: Board leadership clarified — Merit appointed long-time director F. Ann Millner as Chair of the Board effective Jan. 5, 2026, which investors typically view as governance continuity and reduced uncertainty at the top. Merit Medical Appoints F. Ann Millner
• Positive Sentiment: Preliminary Q4 revenue roughly in line-to-slightly-above consensus — Merit provided a projected preliminary unaudited Q4 revenue range (~$389M–$395M) that sits around analyst estimates, supporting its operating momentum heading into FY2026. Preliminary Q4 Revenue
• Neutral Sentiment: Technical backdrop mixed — Shares recently crossed above the 200-day moving average, a constructive technical sign, but the move may also invite profit-taking by short-term traders. Technical Note
• Negative Sentiment: No clear EPS guidance in the Q4 update and elevated volume — The company’s Q4 release omitted a firm EPS number, which can create uncertainty; combined with higher-than-average trading volume, that likely pressured the stock as some investors reduced exposure despite positive revenue and analyst commentary.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.